Journal of Nucleic Acids cytoplasm rather than secreted suggesting an intracellular role for these isoforms [65] as was already demonstrated for VEGF [3]. We can then predict that the combination of anti- angiogenic therapies and targeting of SRPK activity to alter the VEGF/VEGFxxxb balance may improve actual therapies and be a key to increased treatment eﬃciency (Figure 2). Authors’ Contribution C. Hilmi and M. Guyot equally contributed to the paper. Acknowledgments This work was supported by the National Institute of Cancer (INCA), the Association for Cancer Research (ARC), the “Fondation de France”, the “Fondation pour la Recherche Me´dicale” (ﬁnancial support for Caroline Hilmi), and the Ministry for Research and Education (ﬁnancial support for Me´lanie Guyot). The authors gratefully thank Dr. Scott Parks for editorial corrections. References [1] C. Ortholan, J. Durivault, J. M. Hannoun-Levi et al., “Beva- cizumab/docetaxel association is more eﬃcient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic eﬀect of combined treatment,” European Journal of Cancer, vol. 46, no. 16, pp. 3022–3036, 2010. [2] S. Lee, T. T. Chen, C. L. Barber et al., “Autocrine VEGF signaling is required for vascular homeostasis,” Cell, vol. 130, no. 4, pp. 691–703, 2007. [3] T. H. Lee, S. Seng, M. Sekine et al., “Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1,” PLoS Medicine, vol. 4, e186, no. 6, pp. 1101–1116, 2007. [4] S. E. Duﬀ, M. Jeziorska, D. D. Rosa et al., “Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy,” European Journal of Cancer, vol. 42, no. 1, pp. 112–117, 2006. [5] G. Giannelli, A. Azzariti, C. Sgarra, L. Porcelli, S. Antonaci, and A. Paradiso, “ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells,” Biochemical Phar- macology, vol. 71, no. 4, pp. 479–485, 2006. [6] A. D. Yang, E. R. Camp, F. Fan et al., “Vascular endothelial growth factor receptor-1 activation mediates epithelial to mes- enchymal transition in human pancreatic carcinoma cells,” Cancer Research, vol. 66, no. 1, pp. 46–51, 2006. [7] A. Hiramatsu, H. Miwa, M. Shikami et al., “Disease-speciﬁc expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML,” Leukemia and Lymphoma, vol. 47, no. 1, pp. 89–95, 2006. [8] T. Seto, M. Higashiyama, H. Funai et al., “Prognostic value of expression of vascular endothelial growth factor and its ﬂt-1 and KDR receptors in stage I non-small-cell lung cancer,” Lung Cancer, vol. 53, no. 1, pp. 91–96, 2006. [9] P. M. Lacal, F. Ruﬃni, E. Pagani, and S. D’Atri, “An autocrine loop directed by the vascular endothelial growth factor pro- motes invasiveness of human melanoma cells,” International Journal of Oncology, vol. 27, no. 6, pp. 1625–1632, 2005. 5 [10] L. G. Presta, H. Chen, S. J. O’Connor et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Research, vol. 57, no. 20, pp. 4593–4599, 1997. [11] J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. [12] B. Escudier, A. Pluzanska, P. Koralewski et al., “Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial,” Lancet, vol. 370, no. 9605, pp. 2103–2111, 2007. [13] B. I. Rini, S. Halabi, J. E. Rosenberg et al., “Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206,” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5422–5428, 2008. [14] B. Escudier, J. Bellmunt, S. Ne´grier et al., “Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): ﬁnal analysis of overall survival,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2144–2150, 2010. [15] B. I. Rini, S. Halabi, J. E. Rosenberg et al., “Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: ﬁnal results of CALGB 90206,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2137–2143, 2010. [16] R. J. Motzer, G. R. Hudes, B. D. Curti et al., “Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3958–3964, 2007. [17] B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib for treatment of renal cell carcinoma: ﬁnal eﬃcacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3312–3318, 2009. [18] B. I. Rini, G. Wilding, G. Hudes et al., “Phase II study of axi- tinib in sorafenib-refractory metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4462–4468, 2009. [19] C. N. Sternberg, I. D. Davis, J. Mardiak et al., “Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 1061–1068, 2010. [20] M. J. MacKenzie, B. I. Rini, P. Elson et al., “Temsirolimus in VEGF-refractory metastatic renal cell carcinoma,” Annals of Oncology, vol. 22, no. 1, pp. 145–148, 2011. [21] J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, and A. Berkenblit, “Temsirolimus safety proﬁle and management of toxic eﬀects in patients with advanced renal cell carcinoma and poor prognostic features,” Annals of Oncology, vol. 19, no. 8, pp. 1387–1392, 2008. [22] R. J. Motzer, B. Escudier, S. Oudard et al., “Eﬃcacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial,” The Lancet, vol. 372, no. 9637, pp. 449–456, 2008. [23] M. Mita, K. Sankhala, I. Abdel-Karim, A. Mita, and F. Giles, “Deforolimus (AP23573) a novel mTOR inhibitor in clinical development,” Expert Opinion on Investigational Drugs, vol. 17, no. 12, pp. 1947–1954, 2008. [24] A. M. Jubb and A. L. Harris, “Biomarkers to predict the clinical eﬃcacy of bevacizumab in cancer,” The Lancet Oncology, vol. 11, no. 12, pp. 1172–1183, 2010.